Gouty Tophi Within the Carpal Tunnel Leading to Severe Finger Flexion Contracture A Case Report and Short-Term Follow-Up

Why It Matters

Early recognition of gout‑related carpal‑tunnel involvement prevents permanent hand disability and reduces costly delayed interventions, highlighting a niche yet critical intersection of rheumatology and hand surgery.

Key Takeaways

• Gout tophi can infiltrate carpal tunnel, causing contracture
• Misdiagnosis delays treatment, worsening hand function
• Surgical debridement plus uric‑acid therapy restores mobility
• Early imaging essential for accurate diagnosis
• Case highlights need for interdisciplinary management

Pulse Analysis

Gout remains one of the most prevalent inflammatory arthritides worldwide, affecting an estimated 4% of adults in the United States. While chronic hyperuricemia typically manifests as podagra or tophaceous deposits around joints such as the ankle and elbow, involvement of the carpal tunnel is exceptionally rare. This case underscores that tophaceous material can encroach on flexor tendons and the median nerve, producing a severe flexion contracture that mimics primary orthopedic conditions. Recognizing this atypical presentation expands the clinical spectrum of gout and alerts both rheumatologists and hand surgeons to a potential diagnostic blind spot.

Diagnosing tophaceous carpal‑tunnel syndrome demands a high index of suspicion and multimodal imaging. Ultrasound can reveal hyperechoic aggregates within tendon sheaths, while MRI delineates soft‑tissue infiltration and nerve compression with superior contrast. Early imaging not only accelerates definitive care but also averts the cascade of tendon adhesion, muscle atrophy, and irreversible functional loss that drive up healthcare expenditures. From a business perspective, the need for advanced diagnostic tools creates opportunities for imaging manufacturers and specialty clinics to develop targeted protocols for atypical gout presentations.

Therapeutically, the case illustrates the synergy between surgical intervention and sustained pharmacologic control of serum uric acid. Debulking the tophi, releasing adhesions, and decompressing the median nerve restored range of motion, while continuous urate‑lowering therapy—often with xanthine oxidase inhibitors or uricosurics—prevents recurrence. This integrated approach fuels demand for both orthopedic surgical services and the growing portfolio of gout medications, reinforcing the importance of interdisciplinary care pathways. Future research may focus on minimally invasive techniques and biomarker‑guided therapy to further improve outcomes and reduce costs for this niche patient population.